Because cancer cells can be genetically different even a centimeter apart within the same tumor, a single targeting agent will inevitably miss some malignant tissue. The solution is a 'cocktail' of multiple tumor-targeted dyes, each targeting a different marker, to ensure visualization of virtually all cancer variants in a patient.

The trend towards less invasive surgery using smaller incisions and endoscopes reduces a surgeon's ability to see and feel tissue directly. This loss of traditional tactile and visual feedback creates a critical need for new tools. Fluorescence-guided surgery is not just an improvement but a necessary replacement for these lost senses.

Instead of just measuring the presence or quantity of proteins, new technology analyzes their physical proximity and co-localization on a cell's surface. This protein "geography" creates a unique spatial fingerprint that can more accurately distinguish healthy regenerating cells from residual cancer cells post-treatment.

Historically, bladder-sparing options were primarily for patients unfit for radical cystectomy. Now, with advances in surgical techniques and perioperative care, fewer patients are deemed truly ineligible for surgery. This shift means new bladder-sparing strategies are being developed for a much broader patient population.

Histosonics is pioneering the next stage of surgery by using focused sound waves to non-invasively liquefy tumors. This breakthrough technology can treat patients previously deemed non-surgical candidates, improving their condition enough to make them eligible for surgical resection or even organ transplants, creating entirely new therapeutic pathways.

While bladder preservation is a key goal, there is an unavoidable risk. Forgoing definitive local treatment like surgery means a subset of patients will not be cured by systemic therapy alone and will miss their opportunity for a potentially curative operation, a crucial ethical consideration.

With highly effective neoadjuvant therapies now available, the surgeon's role in muscle-invasive bladder cancer is evolving. They are moving from being the primary decider and treater to being a key manager of a 'perioperative bundle,' where their first goal is often to get patients to medical oncology for systemic treatment.

Experts suggest urinary tumor DNA (utDNA) may better reflect local disease in the bladder, while circulating tumor DNA (ctDNA) indicates systemic disease. Using both tests in parallel could provide a more complete picture, with dual-negative results potentially becoming a key criterion for safely pursuing bladder-sparing approaches.

In low-grade gliomas, FET PET can pinpoint metabolically active regions within larger, non-specific areas of flare signal abnormality. This helps neurosurgeons target biopsies or resections to the most aggressive parts of the tumor, potentially identifying transformation to a higher grade.